TRx-237-005 Clinical Study

This clinical trial will assess the safety and efficacy of LMTX™ in up to 700 patients diagnosed with mild Alzheimer’s Disease.  The main measures of efficacy to be used in the study are:

  1. The change in study subjects’ performance at the beginning and the end of the study in two commonly used clinical assessments:
    • The Alzheimer’s Disease Assessment Scale – Cognitive Subscale, known as ADAS-cog11
    • The Modified Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change, known as ADCS-CGIC
  2. The reduction in decline in glucose uptake in the temporal lobe as measured by FDG/PET imaging
  3. The safety and tolerability of LMTX™ given for up to 18 months

The treatment period is 18 months and the study, which is placebo-controlled, is taking place at over 100 clinical sites, primarily in the US and EU. The study is fully recruited and results are expected in the second half of 2016.

First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease

TauRx Completes Recruitment to Phase 3 Alzheimer’s Disease Studies